• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

终末耗竭的 CD8+ T 细胞对 PD-1 阻断有抗性，促进侵袭性癌症干细胞的生成和维持。

Terminally Exhausted CD8+ T Cells Resistant to PD-1 Blockade Promote Generation and Maintenance of Aggressive Cancer Stem Cells.

机构信息

Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute (CNCI), Kolkata, India.

Cancer Biology Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.

出版信息

Cancer Res. 2023 Jun 2;83(11):1815-1833. doi: 10.1158/0008-5472.CAN-22-3864.

DOI:10.1158/0008-5472.CAN-22-3864
PMID:36971604
Abstract

Cross-talk with TTEX CD8+ T cells mediated by the VEGFR2 axis induces aggressive properties in cancer stem cells to promote tumor progression.

摘要

VEGFR2 轴介导的 TTEX CD8+ T 细胞串扰诱导癌症干细胞获得侵袭性特征，从而促进肿瘤进展。

相似文献

1
Terminally Exhausted CD8+ T Cells Resistant to PD-1 Blockade Promote Generation and Maintenance of Aggressive Cancer Stem Cells.终末耗竭的 CD8+ T 细胞对 PD-1 阻断有抗性，促进侵袭性癌症干细胞的生成和维持。
Cancer Res. 2023 Jun 2;83(11):1815-1833. doi: 10.1158/0008-5472.CAN-22-3864.
2
TOX-expressing terminally exhausted tumor-infiltrating CD8 T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer.在膀胱癌中，共阻断 PD-1 和 TIGIT 可重新激活表达 TOX 的终末耗竭肿瘤浸润 CD8 T 细胞。
Cancer Lett. 2021 Feb 28;499:137-147. doi: 10.1016/j.canlet.2020.11.035. Epub 2020 Nov 27.
3
Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors.CD4 T 细胞对脑肿瘤内 CD8 T 细胞耗竭和对 PD-1 阻断治疗反应性的影响。
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005293.
4
Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity.缺氧驱动耗尽的 T 细胞中 CD39 依赖性的抑制功能，从而限制抗肿瘤免疫。
Nat Immunol. 2023 Feb;24(2):267-279. doi: 10.1038/s41590-022-01379-9. Epub 2022 Dec 21.
5
Combinatorial immunotherapy induces tumor-infiltrating CD8 T cells with distinct functional, migratory, and stem-like properties.组合免疫疗法诱导具有不同功能、迁移和干性特征的肿瘤浸润 CD8 T 细胞。
J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-003614.
6
Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer.靶向 CD96 可通过增强宫颈癌中 CD8+TIL 的功能克服 PD-1 阻断耐药性。
J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-003667.
7
PD-1 blockade-unresponsive human tumor-infiltrating CD8 T cells are marked by loss of CD28 expression and rescued by IL-15.PD-1 阻断无应答的人类肿瘤浸润性 CD8 T 细胞表现为 CD28 表达缺失，并可通过 IL-15 挽救。
Cell Mol Immunol. 2021 Feb;18(2):385-397. doi: 10.1038/s41423-020-0427-6. Epub 2020 Apr 24.
8
Subsets of exhausted CD8 T cells differentially mediate tumor control and respond to checkpoint blockade.耗竭的 CD8 T 细胞亚群差异介导肿瘤控制并对检查点阻断产生反应。
Nat Immunol. 2019 Mar;20(3):326-336. doi: 10.1038/s41590-019-0312-6. Epub 2019 Feb 18.
9
Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.在抗 PD-1 耐药肿瘤模型中激活 NKT 细胞通过重新激活耗竭的 CD8 T 细胞增强抗肿瘤免疫。
Cancer Res. 2018 Sep 15;78(18):5315-5326. doi: 10.1158/0008-5472.CAN-18-0734. Epub 2018 Jul 16.
10
Intratumoral Tcf1PD-1CD8 T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy.具有干性特征的肿瘤内 Tcf1PD-1CD8 T 细胞促进接种疫苗和检查点阻断免疫治疗后的肿瘤控制。
Immunity. 2019 Jan 15;50(1):195-211.e10. doi: 10.1016/j.immuni.2018.12.021. Epub 2019 Jan 8.

引用本文的文献

1
Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions.基于嵌合抗原受体的免疫疗法靶向癌症干细胞：生物学、证据及未来方向
Cancer Cell Int. 2025 Jul 28;25(1):289. doi: 10.1186/s12935-025-03846-3.
2
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab.使用抗血管生成药物重塑冷型软组织肉瘤的肿瘤微环境：瑞戈非尼联合阿维鲁单抗的2期试验
Signal Transduct Target Ther. 2025 Jun 27;10(1):202. doi: 10.1038/s41392-025-02278-9.
3
Identification of Prognosis Signature Based on cGAS-STING Pathway and Its Immunotherapeutic Significance in Lung Adenocarcinoma.
基于cGAS-STING通路的肺腺癌预后特征鉴定及其免疫治疗意义
Mol Biotechnol. 2025 Jan 31. doi: 10.1007/s12033-025-01376-x.
4
Stem-like exhausted CD8 T cells in pleural effusions predict improved survival in non-small cell lung cancer (NSCLC) and mesothelioma.胸腔积液中类似干细胞的耗竭性CD8 T细胞预示着非小细胞肺癌（NSCLC）和间皮瘤患者的生存率提高。
Transl Lung Cancer Res. 2024 Sep 30;13(9):2352-2372. doi: 10.21037/tlcr-24-284. Epub 2024 Sep 27.
5
CAR-T cell-derived exosomes: a new perspective for cancer therapy.CAR-T 细胞衍生的外泌体：癌症治疗的新视角。
Stem Cell Res Ther. 2024 Jun 18;15(1):174. doi: 10.1186/s13287-024-03783-4.
6
The immunomodulatory impact of naturally derived neem leaf glycoprotein on the initiation progression model of 4NQO induced murine oral carcinogenesis: a preclinical study.天然来源的印楝叶糖蛋白对 4NQO 诱导的小鼠口腔致癌起始进展模型的免疫调节作用：一项临床前研究。
Front Immunol. 2024 Mar 22;15:1325161. doi: 10.3389/fimmu.2024.1325161. eCollection 2024.
7
Circulating T cells: a promising biomarker of anti-PD-(L)1 therapy.循环 T 细胞：抗 PD-(L)1 治疗的有前途的生物标志物。
Front Immunol. 2024 Mar 21;15:1371559. doi: 10.3389/fimmu.2024.1371559. eCollection 2024.
8
PX-478, an HIF-1α inhibitor, impairs mesoCAR T cell antitumor function in cervical cancer.PX-478，一种缺氧诱导因子-1α（HIF-1α）抑制剂，会损害间皮素嵌合抗原受体T细胞（mesoCAR T cell）在宫颈癌中的抗肿瘤功能。
Front Oncol. 2024 Feb 15;14:1357801. doi: 10.3389/fonc.2024.1357801. eCollection 2024.
9
Cancer stem cell-immune cell crosstalk in breast tumor microenvironment: a determinant of therapeutic facet.肿瘤微环境中癌症干细胞-免疫细胞的相互作用：治疗方面的决定因素。
Front Immunol. 2023 Nov 27;14:1245421. doi: 10.3389/fimmu.2023.1245421. eCollection 2023.
10
The diverse effects of transforming growth factor-β and SMAD signaling pathways during the CTL response.CTL 应答过程中转化生长因子-β和 SMAD 信号通路的多样化效应。
Front Immunol. 2023 Jun 23;14:1199671. doi: 10.3389/fimmu.2023.1199671. eCollection 2023.